James R. Berenson

Dr. James R. Berenson


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in The Lancet Oncology
Verified
Journal Article
Closed access
JBJames Berenson
James Berenson
RPRobert Pflugmacher
Robert Pflugmacher
PJPeter Jarzem
Peter Jarzem
JZJeffrey Zonder
Jeffrey Zonder
KSKenneth Schechtman
Kenneth Schechtman
CICancer Patient Fracture Evaluation (CAFE) Investigators
Cancer Patient Fracture Evaluation (CAFE) Investigators

18 July 2012 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
ESEric Sanchez
Eric Sanchez
MLMingjie Li
Mingjie Li
AKAlex Kitto
Alex Kitto
JLJennifer Li
Jennifer Li
CWCathy S. Wang
Cathy S. Wang
JBJames Berenson
James Berenson
Summary: Although TNFRSF17 (also designated as B‐cell maturation antigen (BCMA)) is expressed on tumour cells in B‐cell malignancies, it has not been found in serum. The present study found that BCMA concentrations were higher in the supernatants of cultured bone marrow mononuclear cells from multiple myeloma (MM) patients than in healthy subjects. Serum BCMA levels were measured in samples from MM patients (n = 209), monoclonal gammopathy of undetermined significance (MGUS) individuals (n = 23) and age‐matched controls (n = 40). BCMA was detected in the serum of untreated MM patients (n = 50) and levels were higher than in MGUS patients (P = 0·0157) and healthy subjects (P < 0·0001). Serum BCMA levels were higher among patients with progressive disease (n = 80) compared to those with responsive disease (n = 79; P = 0·0038). Among all MM patients, overall survival was shorter among patients whose serum BCMA levels were above the median (P = 0·001). We also demonstrated that sera from mice with human MM xenografts contained human BCMA, and levels correlated with the change in tumour volume in response to melphalan or cyclophosphamide with bortezomib. These results suggest that serum BCMA levels may be a new biomarker for monitoring disease status and overall survival of MM patients.

29 December 2016 in Haematologica
Verified
Journal Article
Open access
PDF file
MGMichael Ghermezi
Michael Ghermezi
MLMingjie Li
Mingjie Li
SVSuzie Vardanyan
Suzie Vardanyan
NHNika Manik Harutyunyan
Nika Manik Harutyunyan
JGJillian Gottlieb
Jillian Gottlieb
JBJames Berenson
James Berenson
B-cell maturation antigen is expressed on plasma cells. In this study, we have identified serum B-call maturation antigen as a novel biomarker that can monitor and predict outcomes for multiple myeloma patients. Compared to healthy donors, patients with multiple myeloma showed elevated serum B-cell maturation antigen levels (P < 0.0001). Serum B-cell maturation antigen levels correlated with the proportion of plasma cells in bone marrow biopsies (Spearman rho = 0.710; P < 0.001), clinical status (P values: 0.0374 complete response vs partial response; < 0.0001 complete response vs. progressive disease), and tracked with changes in M protein levels. Among patients with non secretory disease, serum B-cell maturation antigen levels correlated with bone marrow plasma cell levels and PET scan findings. Kaplan-Meier analysis demonstrated that serum B-cell maturation antigen levels above the median levels were predictive of a shorter progression-free survival (PFS; P = 0.0006) and overall survival (OS; P = 0.0108) among multiple myeloma patients (n = 243). Specifically, patients with serum B-cell maturation antigen levels above the median level at the time of starting frontline (P = 0.0043) or a new salvage therapy (P = 0.0044) were found to have shorter progression-free survival. Importantly, serum B-cell maturation antigen levels did not show any dependence on renal function and maintained independent significance when tested against other known prognostic markers for multiple myeloma such as age, β2M, hemoglobin, and bone disease. These data identify serum B-cell maturation antigen as a new biomarker to manage multiple myeloma patients.

15 March 2007 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JBJames Berenson
James Berenson
JMJeffrey Matous
Jeffrey Matous
RSRegina A. Swift
Regina A. Swift
RMRussell Mapes
Russell Mapes
BMBlake Morrison
Blake Morrison
HYHoward S. Yeh
Howard S. Yeh
Purpose: This multicenter, open-label, phase I/II dose escalation study assessed the safety/tolerability and initial efficacy of arsenic trioxide/bortezomib/ascorbic acid (ABC) combination therapy in patients with relapsed/refractory multiple myeloma.

9 June 2010 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JBJames Berenson
James Berenson
KAKenneth C. Anderson
Kenneth C. Anderson
RARobert A. Audell
Robert A. Audell
RBRalph V. Boccia
Ralph V. Boccia
MCMorton Coleman
Morton Coleman
RKRobert A. Kyle
Robert A. Kyle
Summary: On February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of undetermined significance (MGUS). This non‐malignant B‐cell disorder is the most common plasma cell dyscrasia and is associated with an increased risk of developing serious B‐cell disorders. Individuals with MGUS also have an increased risk of osteoporosis and osteopenia associated with an increased likelihood of developing fractures especially in the vertebral column, peripheral neuropathy and thromboembolic events. The goal of the meeting was to develop a consensus statement regarding the appropriate tests to screen, evaluate and follow‐up patients with MGUS. The panel also addressed the identification and treatment of MGUS‐related skeletal problems, thromboembolic events and neurological complications. The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.

1 March 2003
Verified
Journal Article
Closed access
MMMark H Ma
Mark H Ma
HYHank H Yang
Hank H Yang
KPKimberly Parker
Kimberly Parker
SMSteven Manyak
Steven Manyak
JFJeffrey M Friedman
Jeffrey M Friedman
JBJames Berenson
James Berenson